Announced details
Dysmenorrhea
ASKA Pharmaceutical has licensed in this product from Insud Pharma.
Headquartered in Madrid, Spain. Insud Pharma has operated in the pharmaceutical and healthcare sectors for more than 45 years and has 9,000 employees worldwide. It develops and manufactures pharmaceuticals and pharmaceutical ingredients through 3 business units: Industrial (Chemo), Branded (Exeltis), and Biotechnology (mAbxience).
9,000 Insud Pharma employees
The impact on consolidated results for the fiscal year ending March 2027 has already been incorporated.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drospirenone product (LPRI-CF113), PROFILE-D |
| Counterparty | Insud Pharma |
| Counterparty overview | Headquartered in Madrid, Spain. Insud Pharma has operated in the pharmaceutical and healthcare sectors for more than 45 years and has 9,000 employees worldwide. It develops and manufactures pharmaceuticals and pharmaceutical ingredients through 3 business units: Industrial (Chemo), Branded (Exeltis), and Biotechnology (mAbxience). |
| Relationship with the Company | ASKA Pharmaceutical has licensed in this product from Insud Pharma. |
| Launch date | Domestic Phase III clinical trial initiated on 4 November 2026 (actual) |
| Applicable area | Dysmenorrhea |
| Location scale | 9,000 Insud Pharma employees |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 has already been incorporated. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To directly compare the efficacy and safety of this product with those of an existing progestin product. Through the development of this product, ASKA Pharmaceutical aims to create a new treatment option for dysmenorrhea and contribute to improving women's health and quality of life.